In response to the favourable outcomes of the MORDOR trial, REACH Nigeria is actively implementing mass drug administration (MDA) to reduce under-5 mortality, targeting the age group of 1-59 months in states with at least 60/1000 infant mortality. The pilot phase commenced in Abia, Akwa-Ibom, Jigawa, Kebbi, Kano, and Sokoto with plans for nationwide scale-up to 12 additional states from 2024 to 2027, starting with Sokoto in Q2,2024.
Solina currently provides technical assistance (TA) to the Federal Ministry of Health, focusing on devising an effective phasing plan and ensuring a consistent supply of Azithromycin, the pivotal drug employed in the mass drug administration (MDA)-Azithromycin approach; for a successful roll-out and expansion. This project aims to reduce under-5 mortality rates and enhance child survival in Nigeria and this is in response to the favourable outcomes of the MORDOR trial.
REACH Nigeria is actively implementing mass drug administration (MDA) to reduce under-5 mortality, targeting the age group of 1-59 months in states with at least 60/1000 infant mortality. The pilot phase commenced in Abia, Akwa-Ibom, Jigawa, Kebbi, Kano, and Sokoto with plans for nationwide scale-up to 12 additional states from 2024 to 2027, starting with Sokoto in Q2,2024.
